Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6564 participants.

Also called NCT02504216

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 6,564 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02504216
  • EudraCT 2014-005569-58
Other papers using this trial's data
  • Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial Circulation, 2021-10-05 DOI, PubMed 34380322
  • Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial Circulation. Cardiovascular interventions, 2026-05 DOI, PubMed 41757414
  • Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety Circulation, 2020-12-08 DOI, PubMed 33138628
  • Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD Journal of the American Heart Association, 2025-11-04 DOI, PubMed 41128134, PMC12684792 In the PMC Open Access subset under CC BY-NC-ND.
  • Rivaroxaban in Peripheral Artery Disease after Revascularization The New England journal of medicine, 2020-05-21 DOI, PubMed 32222135
  • Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits Journal of vascular surgery, 2023-04 DOI, PubMed 36470531
  • Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD Journal of the American College of Cardiology, 2021-11-02 DOI, PubMed 34711335, PMC12698318 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD Journal of the American Heart Association, 2022-06-21 DOI, PubMed 35699170, PMC9238670 In the PMC Open Access subset under CC BY-NC.
  • Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial Journal of the American College of Cardiology, 2021-07-27 DOI, PubMed 34010631

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Japan, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02504216. Randomized; quadruple masking; primary purpose prevention. Start 2015-08-18 (actual); primary completion 2019-11-27 (actual). Results posted on 2020-12-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Acronym
VOYAGER PAD
Condition
Peripheral Artery Disease
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939)
Intervention (Drug)
Rivaroxaban-Placebo
Lead sponsor
Bayer (class: industry)
Collaborator
Janssen Research & Development, LLC (class: industry)
Collaborator
Colorado Prevention Center (class: other)

Record details

Record id
cardio:ct-nct02504216
Content hash
841e6712a185a9d24c82537994d7d78a0c3e17873d505a63b4c3d2e519f89176